Close

GSK signs agreement to acquire Nanjing MeiRui Pharmaceuticals

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

GlaxoSmithKline plc announced that it has entered into an agreement to acquire Nanjing MeiRui Pharma Co., Ltd (MeiRui) for a cash consideration of approximately $70 million. Ninety per cent of the share capital of MeiRui is to be acquired from Pagoda Pharmaceuticals Limited and the remaining ten per cent from Allergon AB in a move to further expand GSK’s presence in China, one of the fastest-growing and most significant of the emerging markets.

MeiRui is a leading Chinese pharmaceutical business with a strong portfolio of urology and allergy products, including Prostat for benign prostatic hyperplasia and Sheniting for overactive bladder syndrome. GSK will gain access to this portfolio of products, as well as MeiRui’s established sales and marketing platform and a manufacturing facility in Nanjing City, Jiangsu Province, China.

 

Latest stories

Related stories

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back